重组人血管内皮抑制素联合化疗一线治疗晚期转移性结直肠癌的疗效观察.pdfVIP

现代肿瘤医学 2015年09月 第23卷第17期 MODERN ONCOLOGY，ep.2015，VOL.23，NO.17 ·2459 · 重组人血管内皮抑制素联合化疗一线治疗晚期转移性结直肠癌的疗效 观察 綦晓艳，余宗阳，欧阳学农，王文武 Ｃｌｉｎｉｃａｌ ｏｂｓｅｒｖａｔｉｏｎ ｏｆ Ｒｈ -ｅｎｄｏｓｔａｔｉｎ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｃｈｅｍｏｔｈｅｒａｐｙ ｉｎ ｔｈｅ ｆｉｒｓｔ ｌｉｎｅ ｔｒｅａｔ- ｍｅｎｔ ｏｆ ｍｅｔａｓｔａｔｉｃ ｃｏｌｏｒｅｃｔａｌ ｃａｎｃｅｒ Qi Xiaoyan，Yu Zongyang，Ouyang Xuenong，Wang Wenwu Department of Oncology，Nanjing Military Command Fuzhou GeneralHospital，Key Department of National Traditional ChineseMedicine WesternMedicine，Fujian Fuzhou350025，China. 【Abstract】 Objective：To analyze theefficacy andsafetyof Rh-endostatin（endostar）combinedwithchemothera- py in the treatment of metastaticcolorectal cancer.Methods：All60 metastaticcolorectal cancerpatientsweredivided into the test group（n＝30）and the control group（n＝30）.The control groupwastreatedwith chemotherapy regimen FOLFOX4，the test group wastreatedbyEndostarcombinedwithFOLFOX4 scheme.Results：Theresponserateswere 53.3％ in test group and36.7％ in control group respectively（P0.05），the disease control ratewere83.3％ and 73.3％（P0.05）.The median progression -free survival in test group and control group were 7.3 months ver- sus5.3 months（P0.05）and median overall survival were 11.6 monthsversus9.3 months（P0.05）.Among27 cases of liver metastaseswere subgroup analysis，differenceonthetest group andthecontrol group RRandDCRhad statistical significance（P0.05），butdifferenceonPF andO hadnostatistical significance（P0.05）.Themajor toxicitieswere myelosuppression，gastrointestinal symptoms，neurotoxicity，most in grade I -II.After chemotherapy， QOL ofpatientsweremoreimprovedthanbeforetreatment.AftertreatmenttheCEAandCA199levelsdecreasedobvi- ously，furtheremore，the test groupdecreasedmoreobviouslythanthecontrolgroup.Conclusion：Rh-endostatincom- binedwith chemotherapy in the treatment of metastatic colorectal cancer is safe and effective，and also improves pro-